Acumen Pharmaceuticals, Inc.

NASDAQ:ABOS

Biotechnology

Healthcare
$2.29 +0.67%

+$0.02 today

Market cap
$165.63M
Beta
0.35
P/E (TTM)
-1.3
EPS (TTM)
-$1.79
52W Low $1.10High $3.60

Volume 0.81M

Average 0.40M

ABOS Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Acumen Pharmaceuticals, Inc.NASDAQ: ABOS

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures turns positive

Q1 FY2026 capital expenditures was $0, compared with -$79K a year earlier. Trailing-twelve-month capital expenditures was -$9K. Over 3 fiscal years it compounded at -18.2% a year.

Context

  • Capital expenditures grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly capital expenditures holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$2.25K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
-$88K+450.0% YoY
LTMMar 2026
-$9K-89.3% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year+450.0%——
3-year CAGR-18.2%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(88K) USD
Year-over-year change
-450.0%

Capital Expenditures vs competitors

How ABOS compares with its peers on the latest reported figures

  • ABOS's LTM Mar 2026 capital expenditures of $9K is the 6th largest of the 10 companies compared; the peer median is $139K.
  • Its year-over-year change of -89.3% is the 6th highest of 8, against a peer median of -59.4%.
  • Over three fiscal years its annual growth of -18.2% compares with a peer median of -57.7%.
ABOS Competitors Peer median
Capital Expenditures for ABOS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FATEFate Therapeutics, Inc.LTM Mar 2026$5M +171.5%-44.9%79.1%
SEERSeer, Inc.LTM Mar 2026$1.41M -59.4%-44.1%9.4%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$226.33K -55.8%-33.4%—
MCRBSeres Therapeutics, Inc.LTM Mar 2026$218K -38.1%-70.5%19.0%
ALECAlector, Inc.LTM Mar 2026$139K -81.3%-78.5%0.8%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$9K -89.3%-18.2%—
AGENAgenus Inc.LTM Mar 2026$1K -99.8%-77.9%0.0%
ACTUActuate Therapeutics IncLTM Mar 2026$6 -220.0%——
IRDOpus Genetics, Inc.LTM Mar 2026$0 ——0.0%
SPROSpero Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding ABOS) $139K-59.4%-57.7%0.8%

Competitors are the stored peer set for ABOS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(100.61M)(42.86M)(52.37M)(102.33M)(121.34M)
Depreciation & Amortization4K169K184K178K(751K)
Deferred Income Tax00000
Stock-Based Compensation922K3.06M6.15M9.64M9.85M
Change in Working Capital298K3.99M3.87M11.65M(5.12M)
Accounts Receivables00000
Inventory00000
Accounts Payables557K552K(261K)4.27M(5.09M)
Other Working Capital(259K)3.43M4.13M7.38M(25K)
Other Non-Cash Items81.42M487K(888K)(5.35M)1.82M
Operating Cash Flow(17.96M)(35.15M)(43.06M)(86.22M)(115.54M)
Capital Expenditures(40K)(161K)(21K)(16K)(88K)
Acquisitions (Net)0(39.35K)3K00
Purchases of Investments(104.08M)(41.51M)(250.63M)(170.73M)(38.06M)
Sales of Investments080.86M78.98M218.77M172.08M
Other Investing Activities039.35K000
Investing Cash Flow(104.12M)39.19M(171.67M)48.03M133.93M
Debt Repayment0030M(739K)0
Common Stock Issued168.56M3.79M121.9M7.94M39K
Common Stock Repurchased000(41K)(73K)
Dividends Paid00000
Other Financing Activities1.88M115K(151K)(230K)0
Financing Cash Flow200.47M3.91M151.75M6.93M(34K)
Effect of Forex Changes00000
Net Change in Cash78.39M7.94M(62.98M)(31.26M)18.36M
Free Cash Flow(18M)(35.31M)(43.09M)(86.23M)(115.63M)

Acumen Pharmaceuticals, Inc.

NASDAQ:ABOS

Intrinsic Alpha fair value

Locked

Current Price

$2.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.